Format

Send to

Choose Destination
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Author information

1
Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA;
2
Department of Pathology, Hospital Clinic, University of Barcelona, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain;
3
Haematopathology Unit, European Institute of Oncology, Milan, and Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Medical School, Bologna, Italy;
4
Department of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, MA;
5
Pathodiagnostik, Berlin, Germany;
6
Institute of Human Genetics, Christian Albrechts University Kiel, Kiel, Germany;
7
Division of Oncology, Department of Medicine, Stanford University, Stanford, CA;
8
Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;
9
Department of Hematology, Hospices Civils de Lyon, and Université Claude Bernard Lyon-1, Lyon, France;
10
Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; and.
11
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD.

Abstract

A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.

PMID:
26980727
PMCID:
PMC4874220
DOI:
10.1182/blood-2016-01-643569
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center